This is a new strategy but leans into the wider Baillie Gifford Group and aims to take advantage of the positive impact of biology to health and the health care industry. They see that the changes happening are a biological revolution that push our understanding of biology, with sequencing the genome being the principal driver behind this.
The pace of change is getting faster every day and they want to invest in companies that are transforming the healthcare industry. They invest across five buckets: understanding of diseases, diagnostics, treatment, prevention, and operational efficiency….read more